Company / Cash & Equivalents
Day One Biopharmaceuticals, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$197.1M
FY2025
5-year range
$85.3M / $284.3M
FY2021-FY2025
Trend
+57.7%
vs FY2024
Sector context
#90 of 209
Health Care
What the data says
At $197M, Day One Biopharmaceuticals, Inc.'s cash & equivalents ranks #90 of 209 in the Health Care sector. Cash & Equivalents has fluctuated over the past 7 years, ranging from $27M in FY2019 to $284M in FY2021.
Based on SEC 10-K filings.
$197M in FY2025 with a 5-year CAGR of +35.1%.
Declined from $231M to $197M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +32.2%
- 5-Year CAGR
- +35.1%
- 10-Year CAGR
- -
Sector benchmark
#90 of 209 in Health CareTop 43% of 209This company $197.1M Sector average $696.0M
▼
-71.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +35.1%, indicating consistent growth.
- In FY2025, cash & equivalents increased 57.7% year-over-year.
- Ranks #90 out of 209 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $197.1M | +57.7% |
| FY2024 | $125.0M | -45.9% |
| FY2023 | $230.8M | +170.7% |
| FY2022 | $85.3M | -70.0% |
| FY2021 | $284.3M | +550.2% |
| FY2020 | $43.7M | +60.0% |
| FY2019 | $27.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026